On Wednesday, BofA Securities adjusted its outlook on Incyte (NASDAQ:INCY) Corporation (NASDAQ:INCY), a biopharmaceutical company, by lowering its price target from $66.00 to $64.00, while keeping a neutral rating on the stock. The revision follows Incyte's announcement of its acquisition of Escient Pharmaceuticals, including their pioneering oral MRGPR antagonists, EP262 and EP547.
EP262 is currently undergoing two phase 2 studies for Chronic Spontaneous Urticaria (CSU) and Atopic Dermatitis (AD), and a phase 1b study for Chronic Inducible Urticaria (CIndU). EP547 is being evaluated in a phase 2a trial for cholestatic pruritus (CP). Findings from these studies are anticipated in early 2025.
According to BofA Securities, the acquisition is a strategic fit for Incyte's existing immunology and inflammation (I&I) pipeline and could present new product launch possibilities in 2029. This potential expansion is noted as particularly timely, as it could follow shortly after the loss of exclusivity (LOE) for Incyte's Jakafi in 2028.
While the acquisition is seen as a positive move due to the novel mechanism of action of the acquired drugs, BofA Securities pointed out that there are risks of possible delays in the projected timelines. The firm also stated that it would await further clinical validation before attributing standalone value to these programs.
The new price target reflects a cautious outlook, as BofA Securities does not anticipate any significant revenue from these programs until the end of the decade. Incyte's strategic move aims to bolster its portfolio with innovative treatments, yet the financial impact of this expansion is projected to be several years away.
InvestingPro Insights
In light of the recent strategic acquisition by Incyte Corporation (NASDAQ:INCY), current InvestingPro data and tips offer additional perspective for investors considering the company's stock. With a market capitalization of $11.59 billion and a P/E ratio standing at 19.48, Incyte appears to be trading at a valuation that's reflective of its near-term earnings growth potential. This is further supported by the company's PEG ratio of 0.26, suggesting that the stock may be undervalued in relation to its earnings growth.
InvestingPro Tips highlight that Incyte holds more cash than debt, indicating a strong balance sheet, and the stock is currently in oversold territory based on the RSI. These factors could present a buying opportunity for investors. Moreover, the company's ability to cover interest payments with its cash flows and the fact that it has liquid assets exceeding short-term obligations provide additional financial stability. Notably, Incyte is trading near its 52-week low, which could be an attractive entry point for long-term investors, especially considering that analysts predict profitability this year. With 10 additional InvestingPro Tips available, investors can gain more in-depth insights by visiting https://www.investing.com/pro/INCY and using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.